Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 8Recruiting 8Completed 7Unknown 5Withdrawn 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 39Myelodysplastic Syndromes 15Leukemia, Myelomonocytic, Chronic 11Leukemia 4Myeloproliferative Disorders 3Anemia, Refractory, with Excess of Blasts 3Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Thrombocytosis 1Thrombocythemia, Essential 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Cisplatin 6Bortezomib 6Gemcitabine 5venetoclax 4elotuzumab 4isatuximab 3Vincristine 3Radiotherapy 3Prednisone 3Letrozole 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2palbociclib 2ixazomib 2dexamethasone 21-phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × Azacitidine × Clear all
NCT04086264 2025-08-14

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

AbbVie

Phase 1/2 Active not recruiting
218 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡